Tom D. Spitzer

Tom D. Spitzer

Auto-generated profile, based on publicly available information

Tom D. Spitzer

Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2024 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
SBScott D Bell
Scott D Bell
AQAnthony Quinn
Anthony Quinn
TSTom D. Spitzer
Tom D. Spitzer
BVBrady B. Voss
Brady B. Voss
MWMark R Wakefield
Mark R Wakefield
YFYujiang Fang
Yujiang Fang
Bladder cancer is a leading cancer type in men. The complexity of treatment in late-stage bladder cancer after systemic spread through the lymphatic system highlights the importance of modulating disease-free progression as early as possible in cancer staging. With current therapies relying on previous standards, such as platinum-based chemotherapeutics and immunomodulation with Bacillus Calmette-Guerin, researchers, and clinicians are looking for targeted therapies to stop bladder cancer at its source early in progression. A new era of molecular therapies that target specific features upregulated in bladder cancer cell lines is surfacing, which may be able to provide clinicians and patients with better control of disease progression. Here, we discuss multiple emerging therapies including immune checkpoint inhibitors of the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway, antibody-drug conjugates, modulation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) cell proliferation pathway, chimeric antigen receptor T-cell therapy, and fibroblast growth factor receptor targeting. Together, these modern treatments provide potentially promising results for bladder cancer patients with the possibility of increasing remission and survival rates.